Minirin (Desmopressin Acetate)

Desmopressin acetate is a synthetic analogue of the natural hormone vasopressin. It selectively activates V2 receptors on renal collecting‑duct cells, triggering a cascade that raises intracellular cAMP and inserts aquaporin‑2 channels into the membrane. This enhances water permeability, allowing the kidneys to reabsorb more free water and produce concentrated urine.

The dose of Minirin is individualized for each patient. A qualified prescriber determines the appropriate strength, frequency, and duration based on the specific indication, age, renal function, and response to therapy. Patients should follow the prescribing information and never adjust the dose without medical advice.

Safety data for desmopressin acetate in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To order Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any required import documentation.

Minirin is a synthetic vasopressin analogue that offers a longer half‑life and greater selectivity for V2 receptors compared with natural vasopressin. This results in more predictable dosing and fewer cardiovascular side effects. Alternative treatments include natural vasopressin preparations and other analogues, but Minirin’s oral tablet form provides convenient administration for many patients.

Minirin tablets should be stored at ambient temperature, below 25 °C. Keep the product in its original blister pack or container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Minirin is supplied as an oral tablet. The tablet should be swallowed whole with a glass of water, usually at the same time each day. For nocturnal indications, it is commonly taken 30–60 minutes before bedtime, but exact timing should follow the prescribing clinician’s instructions.

The most serious risks involve severe hyponatremia and water intoxication, which can lead to seizures, coma, or cerebral edema. Patients must monitor fluid intake and serum sodium levels, especially during the initial weeks of therapy or when dose adjustments are made.

Minirin is contraindicated in patients with existing hyponatremia, uncontrolled hypertension, severe renal impairment, or known hypersensitivity to desmopressin acetate. Caution is also advised for individuals on chronic diuretic therapy or those who cannot reliably monitor fluid balance.